附近上门

While they鈥檙e not favorite subjects for sharing personal experiences, incontinence and medical issues around urination are incredibly common.

Adult women are particularly vulnerable. It鈥檚 estimated that roughly half are to some degree, with prevalence rising sharply with age. Men are also .

With senior populations across industrialized nations, treating and managing these conditions has proven increasingly costly as well. Global spending on adult diapers and other incontinence products is projected to $9.7 billion in 2025 and rise steadily in coming years. The market for treatment devices, currently at over $4 billion annually, is expected to grow even faster.

Bottom line: For a topic that people mostly avoid bringing up in casual conversation, incontinence represents a huge addressable market. And startup founders and investors have taken note.

Funding rounds abound

Per 附近上门 , more than a dozen companies tied to incontinence and urinary health have raised funding rounds in 2024 and 2025. Our sample cohort, listed below, has collectively raised over $500 million to date.

It鈥檚 a diverse lineup, both in geography and specialization, although a majority are medical device startups.

In this area, the most recent big round went to , a startup developing a stent to alleviate lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH), a noncancerous enlargement of the prostate gland that occurs as men age. The Dublin-based company closed on $80 billion in Series B funding this week.

Neuromodulation

In terms of total funding to date, the leading name on our list is , developer of a neuromodulation therapy for urinary urge incontinence, an overactive bladder symptom it affects 1 in 5 U.S. women. San Jose-based Neuspera has raised $135 million in known funding to date, per 附近上门 .

Neuspera is also progressing on the commercialization front. This summer, it received FDA approval for a miniaturized neurostimulator implant said to be effective in reducing or eliminating urinary leaks.

, based in Valencia, California, is also applying neuromodulation technology to treat bladder dysfunction. The 14-year-old company raised up to $35 million in a financing earlier this year to pursue commercializing the eCoin, a coin-sized neurostimulator implanted under the skin near the ankle. The device delivers periodic stimulation to the tibial nerve with the aim of reduced episodes of incontinence.

Seed and early stage

We鈥檙e also seeing smaller rounds at seed and early stage for startups tackling incontinence.

Two-year-old , for instance, closed on a $9.4 million Series A last year for a system for women to train and strengthen their pelvic floor muscles. And Minnesota-based closed on seed funding last year for an in-home treatment for incontinence and weakened pelvic floor muscles.

On the consumer products side, has also raised multiple seed financings, per 附近上门 , to scale its offerings of disposable leakproof briefs.

A new reason not to talk about incontinence

While it will inevitably take time for the current pipeline of funded startups to scale enough to measurably impact the problems they鈥檙e addressing, the hope is that they will eventually prevail.

If all works out exceedingly well, the expectation is that incontinence will still be a subject people don鈥檛 talk about much. However, it will not be because they鈥檙e embarrassed, but rather because they don鈥檛 have to worry about it.

Related 附近上门 query:

Illustration: